IXICO PLC — Remuneration Information 2020

Jul 6, 2020

National Storage Mechanism | Additional information

RNS Number : 0464S

IXICO plc

06 July 2020

IXICO plc

("IXICO" or the "Company")

Grant of share options

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has granted 450,000 options over the ordinary shares in the Company in accordance with the rules of the Company's EMI Share Option Plan 2014 (the 'Plan') exercisable at a price of 70p (being the closing middle market price per ordinary share on 3 July 2020).

The 450,000 options awarded are split:

i)             300,000 options issued to members of the Company's Senior Leadership Team (the 'SLT Options'); and

ii)            150,000 options issued to other employees within the Company (the 'Employee Options').

The SLT Options are subject to performance conditions linked to revenue and share price accretion across three years. Lammert Albers, Chief Commercial Officer, Robin Wolz, SVP Science & Innovation and Sylke Grootoonk, VP Programme Management receive 100,000 options each under this award.

The Employee Options are subject to performance conditions linked to profitability and retention within the Company across three years.

For further information please contact:

IXICO plc			+44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)				+44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales)
Walbrook PR Ltd	Tel: 020 7933 8780 or IXICO@walbrookpr.com
Paul McManus / Lianne Cawthorne /		Mob: 07980 541 893 / 07584 391 303 /
Alice Woodings		07407 804 654

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHUOUNRRRUBRAR